Table of Contents

2024-9-1

MM-294 Exploring the Link Between High-Risk Cytogenetics and Skeletal Lytic Lesions in African American (AA) Multiple Myeloma (MM) Patients: Insights From a Decade-Long Study

2024-9-1

Autologous Stem Cell Transplantation for Light Chain Amyloidosis: A Single-Center Report

2024-9-1

CML-734 Atypical Chronic Myeloid Leukemia (CML) With ETV6-ABL1 Mutation Managed Successfully With A Third-Generation TKI And Hematopoietic Stem Cell Transplant

2024-9-1

SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis

2024-9-1

Retraction notice to ``P-377 CD38 targeting in multiple myeloma'' [Clinical Lymphoma Myeloma and Leukemia 23 Supplement 2 (2023) S248]

2024-9-1

Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

2024-9-1

CML-644 Treatment Patterns and Adverse Events Among Elderly Newly Diagnosed Patients with Chronic Myeloid Leukemia: A Real-World Analysis of the Medicare Fee-for-Service Population

2024-9-1

MDS-242 Correlation Between Myelodysplastic Syndrome and COVID-19 Infection

2024-9-1

CML-282 Asciminib Once-Daily (QD) Dosing Demonstrates Comparable Tolerability and Efficacy to Twice-Daily (BID) Dosing: Updated Results From the AIM4CML Study in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With Prior Tyrosine Kinase Inhibitor (TKI) Treatment

2024-9-1

MM-491 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

2024-9-1

CT-551 Long-Term Outcomes of Salvage Radiation Therapy in Relapsed/Refractory Large B-Cell Lymphoma Patients After CAR T-Cell Therapy Failure

2024-9-1

Adverse Events (AEs) Among Patients With Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitors and Subsequent Treatment Adjustment: A Large US Commercial Claims Database Analysis

2024-9-1

AML-738 Myeloid Sarcoma and Lymphoid Sarcoma of the Brain: A Case Series

2024-9-1

An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel

2024-9-1

MPN-470 Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia

2024-9-1

ABCL-253 Can Lymphoma Mimic Crohn's Disease?

2024-9-1

ABCL-367 Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL

2024-9-1

ABCL-226 A Twist of Fate: A Case of Sequential Lymphoma

2024-9-1

TCL-046 Nodal T Follicular Helper Cell Lymphoma Angioimmunoblastic Type Treated as a Classic Hodgkin Lymphoma: Case Report

2024-9-1

A Practical Approach to Successful Stem Cell Collection From Multiple Myeloma Patients With Peripheral Blood CD34 Count Less Than 2 .5 cells/µL.

2024-9-1

Nodal T Follicular Helper Cell Lymphoma Angioimmunoblastic Type Treated as a Classic Hodgkin Lymphoma: Case Report

2024-9-1

AML-696 Limited Toxicity and Impressive Outcomes of Upfront Flag-Based Induction in Newly Diagnosed Acute Myeloid Leukemia: An Indian Scenario

2024-9-1

MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

2024-9-1

AML-106 From Clonal Evolution to Posttransplant Relapse—Case Report of Secondary Acute Myeloid Leukemia

2024-9-1

An Unusual Presentation of Erdheim-Chester Disease: A Case Report

2024-9-1

Mutations of Unknown Significance in the FOXO and EGFR Signaling Pathways in Patients With CML

2024-9-1

What Happened: Suddenly or Acute Abdomen? Difficult Case of ATRA-Related Pneumatosis Cystoides Intestinalis

2024-9-1

Central Nervous System Hemorrhage in Acute Promyelocytic Leukemia – a Tertiary Center Experience

2024-9-1

Feasibility of Azacitidine and Venetoclax Followed by High/Intermediate Dose Cytarabine (HIDAC/IDAC) Consolidation in Previously Untreated Acute Myeloid Leukemia Patients Unfit for Intensive Chemotherapy in a Resource Constraint Low-Middle Income Country: A Pilot Study

2024-9-1

Asciminib as a Bridge to Allogenic Transplant in 3 Patients With Relapsed/Refractory Philadelphia Chromosome-Positive ALL or CML Lymphoid Blast Crisis Refractory/Intolerant to Ponatinib

2024-9-1

MCL-063 Clinical Characteristics and Survival Outcomes of Patients with Mantle Cell Lymphoma—a North Indian Tertiary Care Center Experience

2024-9-1

Initial Results From Summit: An Ongoing, 3-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of Bezuclastinib in Adult Patients With Non-Advanced Systemic Mastocytosis (NonAdvSM)

2024-9-1

DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: ELEGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI IN THE EXPERIENCE OF THE GIMEMA LABNET CML NATIONAL NETWORK

2024-9-1

Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma

2024-9-1

AML-490 Deciphering Endothelial and Coagulation Disturbances in Patients With Acute Myeloid Leukemia at High Risk of Early Complications

2024-9-1

Mosunetuzumab With Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

2024-9-1

MM-543 Prognostic Value of Inflammatory Factors in Extramedullary Multiple Myeloma

2024-9-1

CT-252 First 1-Year Results of a New Hematopoietic Stem Cell Transplant Center

2024-9-1

CT-426 Outcomes of Bone Marrow Transplant in ESRD vs Non-ESRD Patients: A Nationwide Analysis

2024-9-1

AML-222 Distinct Clinical and Biological Characteristics of Acute Myeloid Leukemia With Higher Expression of PIWIL4

2024-9-1

MDS-496 Low MS4A3 Expression Inhibits Differentiation of HSPCs in Patients With Myelodysplastic Syndromes

2024-9-1

ABCL-170 Correlation Between 18F-FDG PET/CT Semiquantitative Parameters and Ki-67 Expression in Diffuse Large B-Cell Lymphoma

2024-9-1

AML-728 Clinical, Molecular, and Treatment Characteristics of Long-Term Survivors Amongst Older Adults with IDH1/2-Mutated Acute Myeloid Leukemia Treated with IDH Inhibitors

2024-9-1

ABCL-122 A Rare Case of Large B-cell Lymphoma Presenting as a Large Pericardial Effusion With Tamponade Physiology

2024-9-1

Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial

2024-9-1

Nationwide Study: Assessing Hospitalization Outcomes Among Bone Marrow Transplant Patients With Graft-Versus-Host Disease

2024-9-1

Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients

2024-9-1

Isolated Anemia: An Unusual Solitary Presentation of Intravesical BCGitis

2024-9-1

Case Report of Refractory Large B-Cell Lymphoma With IRF4 Rearrangement

2024-9-1